Welcome guest, Login | Register


Kai Dallmeier


Ph.D. in Biology, University of Freiburg, Germany, 2008

Current position

Postdoctoral researcher, Virology and Chemotherapy section, Rega Institute, University of Leuven
Research interests: Flaviviruses, RNA biology, antiviral therapy, DNA vaccination


  1. Delang, L., Segura Guerrero, N., Tas, A., Querat, G., Pastorino, B., Froeyen, M., Dallmeier, K., Jochmans, D., Herdewijn, P., Bello, F., Snijder, E. J., de Lamballerie, X., Martina, B., Neyts, J., van Hemert, M. J. and Leyssen, P. (2014). Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. J Antimicrob Chemother. (Epub ahead of print)
  2. Debing, Y., Emerson, S. U., Wang, Y., Pan, Q., Balzarini, J., Dallmeier, K. and Neyts, J. (2014). Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon. Antimicrob Agents Chemother 58(1): 267-273.
  3. Debing, Y., Winton, J., Neyts, J. and Dallmeier, K. (2013). Cutthroat trout virus as a surrogate in vitro infection model for testing inhibitors of hepatitis E virus replication. Antiviral Res 100(1): 98-101.
  4. Dallmeier, K. and Neyts, J. (2013). Simple and inexpensive three-step rapid amplification of cDNA 5' ends using 5' phosphorylated primers. Anal Biochem 434(1): 1-3.
  5. Paganelli, M., Dallmeier, K., Nyabi, O., Scheers, I., Kabamba, B., Neyts, J., Goubau, P., Najimi, M. and Sokal, E. M. (2013). Differentiated umbilical cord matrix stem cells as a new in vitro model to study early events during hepatitis B virus infection. Hepatology 57(1): 59-69.
  6. Alen, M. M., Dallmeier, K., Balzarini, J., Neyts, J. and Schols, D. (2012). Crucial role of the N-glycans on the viral E-envelope glycoprotein in DC-SIGN-mediated dengue virus infection. Antiviral Res 96(3): 280-287.
  7. Rocha-Pereira, J., Jochmans, D., Dallmeier, K., Leyssen, P., Cunha, R., Costa, I., Nascimento, M. S. and Neyts, J. (2012). Inhibition of norovirus replication by the nucleoside analogue 2'-C-methylcytidine. Biochem Biophys Res Commun 427(4): 796-800.
  8. Rocha-Pereira, J., Jochmans, D., Dallmeier, K., Leyssen, P., Nascimento, M. S. and Neyts, J. (2012). Favipiravir (T-705) inhibits in vitro norovirus replication. Biochem Biophys Res Commun 424(4): 777-780.
  9. Mastrangelo, E., Pezzullo, M., De Burghgraeve, T., Kaptein, S., Pastorino, B., Dallmeier, K., de Lamballerie, X., Neyts, J., Hanson, A. M., Frick, D. N., Bolognesi, M. and Milani, M. (2012). Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug. J Antimicrob Chemother 67(8): 1884-1894.
  10. Paeshuyse, J., Dallmeier, K. and Neyts, J. (2011). Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. Curr Opin Virol 1(6): 590-598.
  11. Obeid, S., Printsevskaya, S. S., Olsufyeva, E. N., Dallmeier, K., Durantel, D., Zoulim, F., Preobrazhenskaya, M. N., Neyts, J. and Paeshuyse, J. (2011). Inhibition of hepatitis C virus replication by semi-synthetic derivatives of glycopeptide antibiotics. J Antimicrob Chemother 66(6): 1287-1294.
  12. Charlier, N., Davidson, A., Dallmeier, K., Molenkamp, R., De Clercq, E. and Neyts, J. (2010). Replication of not-known-vector flaviviruses in mosquito cells is restricted by intracellular host factors rather than by the viral envelope proteins. J Gen Virol 91(Pt 7): 1693-1697.
  13. Dallmeier, K., Schultz, U. and Nassal, M. (2008). Heterologous replacement of the supposed host determining region of avihepadnaviruses: high in vivo infectivity despite low infectivity for hepatocytes. PLoS Pathog 4(12): e1000230.
  14. Nassal, M., Leifer, I., Wingert, I., Dallmeier, K., Prinz, S. and Vorreiter, J. (2007). A structural model for duck hepatitis B virus core protein derived by extensive mutagenesis. J Virol 81(23): 13218-13229.
  15. Nassal, M., Dallmeier, K., Schultz, U. and Sun, D. (2005). Phenotyping hepatitis B virus variants: from transfection towards a small animal in vivo infection model. J Clin Virol 34 Suppl 1: S89-95.
Protocols by Kai Dallmeier
  1. Infectious Virus Yield Assay for Hepatitis E Virus
  2. Luminescence-based Antiviral Assay for Hepatitis E Virus